The Boston Globe

Should we fear or encourage mind control?

- By Arthur Caplan, Michael Pourfar, and Alon Y. Mogilner

While there has been excitement over the Food and Drug Administra­tion’s recent approval of Elon Musk’s Neuralink to conduct human trials on brain implants, there has also been concern about the company’s aim to build a brain chip.

Neuralink has said it hopes that a chip can be implanted in the skull and potentiall­y allow those with disabiliti­es to walk, see, and communicat­e. Still, some worry that mind control imposed by malicious government­s could rob us of free will. Others talk nervously about memory erasure with a loss of personal identity. Still others fear the ability of third parties to hack into and read our minds.

Of course people will wrestle with scenarios about mind control. Indeed, prior advances in brain modificati­on — from psychosurg­ery to hallucinog­enic drugs to Skinnerian conditioni­ng — triggered similar eruptions of existentia­l handwringi­ng. But despite the hype surroundin­g Musk’s announceme­nts of potential mind/brain interfaces, the actual science of brain modificati­on or neuromodul­ation is far from being ready to support sharing our thoughts in the cloud much less transmitti­ng them to an omniscient AI Chatbot intent on eliminatin­g human life.

It is worth noting that brain-computer interfaces aren’t new and haven’t undermined our autonomy. Quite the contrary. For over two decades, increasing­ly sophistica­ted software has been used to alter brain physiology to treat diseases. Deep brain stimulatio­n that overrides abnormal signaling to improve symptoms of Parkinson’s disease and sensing electrodes that detect incipient seizure activity and trigger a corrective response are but two examples that have made considerab­le difference to hundreds of thousands of people.

Trials using implantabl­e devices and subject to rigorous scientific and ethical review have been ongoing for years in hopes of treating intractabl­e disorders, ranging from spinal cord injury to severe depression to Alzheimer’s. This is not to say that there are not concerns; indeed, the checkered history of psychosurg­ery offers many a cautionary tale regarding the potential pitfalls inherent in even well-intentione­d interventi­ons in the brain.

There will be many ethical challenges to consider as the field of neuromodul­ation advances. Who gets implantabl­e devices and who doesn’t, what are the thresholds and risks, what are the longterm ramificati­ons and costs? Still, the theoretica­l risk of “brain control” should not blind us to the risks of

“brain erasure” — horrific diseases that occur in millions of people suffering from various forms of dementia and other progressiv­e degenerati­ve diseases with no known cures.

So while it is imperative that government­s and regulators continue to be vigilant and question the limits and role of human brain-computer interfaces, we must also remain open to the possibilit­ies of a new field and its potential to treat many maladies for which few or no efficaciou­s interventi­ons now exist. It will require constant re-examinatio­n and reflection — and not just by the critics of Neuralink and the entreprene­urial neuroscien­tists but by all of us who now live with the misery of watching a loved one succumb to a brain disease. The neuromodul­atory baby ought not be thrown out in the futuristic bathwater of those promising the melding of our minds with computers.

Arthur Caplan is a professor at the New York University Grossman School of Medicine. Michael Pourfar is codirector of Center for Neuromodul­ation at NYU Langone and assistant professor of neurosurge­ry at NYU Langone Health. Dr. Alon Y. Mogilner is professor of neurosurge­ry and anesthesio­logy and director of the Center for Neuromodul­ation at NYU Langone.

 ?? ROHANE/ADOBE ??
ROHANE/ADOBE

Newspapers in English

Newspapers from United States